Baseline characteristics of people experiencing homelessness with a recent drug overdose in the PHOENIx pilot randomised controlled trial.
Chronic disease
Drug-related death
Homelessness
Opioid addiction
Polydrug use
Primary health care
Public health
Randomised controlled trial
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
04 04 2023
04 04 2023
Historique:
received:
25
11
2022
accepted:
16
03
2023
medline:
6
4
2023
entrez:
4
4
2023
pubmed:
5
4
2023
Statut:
epublish
Résumé
Drug-related deaths in Scotland are the highest in Europe. Half of all deaths in people experiencing homelessness are drug related, yet we know little about the unmet health needs of people experiencing homelessness with recent non-fatal overdose, limiting a tailored practice and policy response to a public health crisis. People experiencing homelessness with at least one non-fatal street drug overdose in the previous 6 months were recruited from 20 venues in Glasgow, Scotland, and randomised into PHOENIx plus usual care, or usual care. PHOENIx is a collaborative assertive outreach intervention by independent prescriber NHS Pharmacists and third sector homelessness workers, offering repeated integrated, holistic physical, mental and addictions health and social care support including prescribing. We describe comprehensive baseline characteristics of randomised participants. One hundred and twenty-eight participants had a mean age of 42 years (SD 8.4); 71% male, homelessness for a median of 24 years (IQR 12-30). One hundred and eighteen (92%) lived in large, congregate city centre temporary accommodation. A quarter (25%) were not registered with a General Practitioner. Participants had overdosed a mean of 3.2 (SD 3.2) times in the preceding 6 months, using a median of 3 (IQR 2-4) non-prescription drugs concurrently: 112 (87.5%) street valium (benzodiazepine-type new psychoactive substances); 77 (60%) heroin; and 76 (59%) cocaine. Half (50%) were injecting, 50% into their groins. 90% were receiving care from Alcohol and Drug Recovery Services (ADRS), and in addition to using street drugs, 90% received opioid substitution therapy (OST), 10% diazepam for street valium use and one participant received heroin-assisted treatment. Participants had a mean of 2.2 (SD 1.3) mental health problems and 5.4 (SD 2.5) physical health problems; 50% received treatment for physical or mental health problems. Ninety-one per cent had at least one mental health problem; 66% had no specialist mental health support. Participants were frail (70%) or pre-frail (28%), with maximal levels of psychological distress, 44% received one or no daily meal, and 58% had previously attempted suicide. People at high risk of drug-related death continue to overdose repeatedly despite receiving OST. High levels of frailty, multimorbidity, unsuitable accommodation and unmet mental and physical health care needs require a reorientation of services informed by evidence of effectiveness and cost-effectiveness. Trial registration UK Clinical Trials Registry identifier: ISRCTN 10585019.
Sections du résumé
BACKGROUND
Drug-related deaths in Scotland are the highest in Europe. Half of all deaths in people experiencing homelessness are drug related, yet we know little about the unmet health needs of people experiencing homelessness with recent non-fatal overdose, limiting a tailored practice and policy response to a public health crisis.
METHODS
People experiencing homelessness with at least one non-fatal street drug overdose in the previous 6 months were recruited from 20 venues in Glasgow, Scotland, and randomised into PHOENIx plus usual care, or usual care. PHOENIx is a collaborative assertive outreach intervention by independent prescriber NHS Pharmacists and third sector homelessness workers, offering repeated integrated, holistic physical, mental and addictions health and social care support including prescribing. We describe comprehensive baseline characteristics of randomised participants.
RESULTS
One hundred and twenty-eight participants had a mean age of 42 years (SD 8.4); 71% male, homelessness for a median of 24 years (IQR 12-30). One hundred and eighteen (92%) lived in large, congregate city centre temporary accommodation. A quarter (25%) were not registered with a General Practitioner. Participants had overdosed a mean of 3.2 (SD 3.2) times in the preceding 6 months, using a median of 3 (IQR 2-4) non-prescription drugs concurrently: 112 (87.5%) street valium (benzodiazepine-type new psychoactive substances); 77 (60%) heroin; and 76 (59%) cocaine. Half (50%) were injecting, 50% into their groins. 90% were receiving care from Alcohol and Drug Recovery Services (ADRS), and in addition to using street drugs, 90% received opioid substitution therapy (OST), 10% diazepam for street valium use and one participant received heroin-assisted treatment. Participants had a mean of 2.2 (SD 1.3) mental health problems and 5.4 (SD 2.5) physical health problems; 50% received treatment for physical or mental health problems. Ninety-one per cent had at least one mental health problem; 66% had no specialist mental health support. Participants were frail (70%) or pre-frail (28%), with maximal levels of psychological distress, 44% received one or no daily meal, and 58% had previously attempted suicide.
CONCLUSIONS
People at high risk of drug-related death continue to overdose repeatedly despite receiving OST. High levels of frailty, multimorbidity, unsuitable accommodation and unmet mental and physical health care needs require a reorientation of services informed by evidence of effectiveness and cost-effectiveness. Trial registration UK Clinical Trials Registry identifier: ISRCTN 10585019.
Identifiants
pubmed: 37016418
doi: 10.1186/s12954-023-00771-4
pii: 10.1186/s12954-023-00771-4
pmc: PMC10071267
doi:
Substances chimiques
Heroin
70D95007SX
Diazepam
Q3JTX2Q7TU
Banques de données
ISRCTN
['ISRCTN10585019']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
46Informations de copyright
© 2023. The Author(s).
Références
BMC Health Serv Res. 2021 Jan 4;21(1):7
pubmed: 33397341
Arch Intern Med. 2001 Jan 8;161(1):85-91
pubmed: 11146702
Lancet. 2010 May 29;375(9729):1885-95
pubmed: 20511018
BMC Fam Pract. 2015 Oct 13;16:139
pubmed: 26463577
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720910568
pubmed: 32129134
Qual Life Res. 2017 Feb;26(2):489-503
pubmed: 27566732
J Consult Clin Psychol. 1996 Oct;64(5):881-91
pubmed: 8916615
Lancet Public Health. 2022 Sep;7(9):e733-e743
pubmed: 35907410
Psychotherapy (Chic). 2011 Mar;48(1):9-16
pubmed: 21401269
Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
Eur J Public Health. 2019 Feb 1;29(1):182-189
pubmed: 29878097
Lancet. 2014 Oct 25;384(9953):1541-7
pubmed: 25390579
Am J Public Health. 1997 Feb;87(2):217-20
pubmed: 9103100
Eur Respir J. 2013 Sep;42(3):647-54
pubmed: 23258783
Nat Rev Dis Primers. 2022 Jul 14;8(1):48
pubmed: 35835758
J Epidemiol Community Health. 2019 May;73(5):379-387
pubmed: 30777888
BMJ Open. 2013 Jun 20;3(6):
pubmed: 23794542
Psychosomatics. 2009 Nov-Dec;50(6):613-21
pubmed: 19996233
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Addict Sci Clin Pract. 2019 Apr 15;14(1):17
pubmed: 30982468
Psychiatry Res. 2014 Dec 15;220(1-2):549-55
pubmed: 25129560
Addiction. 2002 Aug;97(8):963-7
pubmed: 12144598
BMJ Open. 2022 Dec 16;12(12):e064792
pubmed: 36526321
J Subst Abuse Treat. 2016 Feb;61:47-59
pubmed: 26531892
JAMA Psychiatry. 2020 May 1;77(5):493-502
pubmed: 31876906
Int J Equity Health. 2021 Jan 7;20(1):19
pubmed: 33413396
Drug Alcohol Depend. 2016 May 1;162:51-5
pubmed: 26993373
Br J Gen Pract. 1992 Mar;42(356):116-9
pubmed: 1493028
Milbank Q. 2020 Sep;98(3):700-746
pubmed: 32808709
Wellcome Open Res. 2019 Mar 11;4:49
pubmed: 30984881
BMJ Open. 2018 Apr 7;8(4):e020161
pubmed: 29627814
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
BMJ. 2021 Sep 30;374:n2061
pubmed: 34593508
Am J Psychiatry. 2007 Mar;164(3):393-9
pubmed: 17329462
Br J Gen Pract. 2019 Aug;69(685):e526-e536
pubmed: 31307999
Lancet Public Health. 2020 Jun;5(6):e342-e360
pubmed: 32504587
Health Soc Care Community. 2022 Feb;30(2):448-468
pubmed: 34423491
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Int J Drug Policy. 2021 Jun;92:102859
pubmed: 32712164
BMJ. 2022 Aug 16;378:o2005
pubmed: 35973697
Harm Reduct J. 2020 Jan 31;17(1):10
pubmed: 32005119
Int J Epidemiol. 2009 Jun;38(3):877-83
pubmed: 19304988
J Clin Epidemiol. 2012 Mar;65(3):301-8
pubmed: 22169081
Am J Prev Med. 2005 Nov;29(4):311-9
pubmed: 16242595
Child Youth Serv Rev. 2020 Nov;118:105429
pubmed: 32895586
Lancet. 2014 Oct 25;384(9953):1529-40
pubmed: 25390578
Int J Drug Policy. 2022 Feb;100:103512
pubmed: 34753047
Addict Behav. 2022 Apr;127:107215
pubmed: 34953432
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
Int J Pharm Pract. 2019 Aug;27(4):355-361
pubmed: 30847995